Install
Dermatology
Skin cancer checks, eczema/psoriasis, acne care, and cosmetic dermatology news.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Cardiology & Metabolic Health
- Oncology & Hematology
- Neurology & Neuroscience
- Orthopedics & Sports Medicine
- Respiratory & Pulmonology
- Gastroenterology & Hepatology
- Endocrinology & Hormones
- Nephrology & Urology
- Rheumatology & Autoimmune
- OB‑GYN (Women’s Health)
- Pediatrics & Adolescent Health
- Geriatrics & Healthy Aging
- Ophthalmology & Vision
- ENT (Ear, Nose & Throat)
- Dentistry & Oral Health
Latest in Dermatology
Edesa Biotech gains FDA clearance to expand Phase 2 vitiligo trial
4+ hour, 11+ min ago (740+ words) U.S. enrolment is expected in early 2027, with up to 80 adults testing EB06 against placebo and topline results due late that year. U.S. trial sites can join an ongoing vitiligo study after Edesa Biotech, Inc. NASDAQEDSA reported FDA clearance of its investigational new drug…...
Precision STING delivery could help convert immune-desert tumors into inflamed tumors
1+ hour, 34+ min ago (276+ words) | Newswise Newswise Precision STING delivery could help convert immune-desert tumors into inflamed tumors The cGAS–STING pathway drives cold-to-hot immune phenotype transformation across multiple organs. Newswise — Immune checkpoint inhibitors (ICIs) have transformed cancer care, yet only a subset of patients…...
New Newport Skin Health Clinic Welcomes Dozens Of Visitors For Discovery Evening
3+ hour, 11+ min ago (230+ words) 'Hey Google, play Isle of Wight Radio!' A new independent medical aesthetics and skin health clinic in Newport welcomed dozens of visitors to a special discovery evening yesterday (Thursday). Cala Medical Aesthetics, based at the Innovation Centre on St Cross…...
Edesa Biotech Clears IND for Phase 2 EB06 Study in Vitiligo
4+ hour, 58+ min ago (351+ words) Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Edesa Biotech Clears IND for Phase 2 EB06 Study in Vitiligo About 40 percent of the…...
Lana Kandalaft: Transforming Therapeutic Cancer Vaccine Strategies for Pancreatic Cancer
4+ hour, 35+ min ago (152+ words) Oncodaily Lana Kandalaft: Transforming Therapeutic Cancer Vaccine Strategies for Pancreatic Cancer Lana Kandalaft, Chief of Clinical and Translational Research at Swiss Medical Network, shared on LinkedIn: “We are very pleased to see our review entitled ‘Strategies to develop therapeutic cancer…...
Intravenous STING Agonist Supercharges Radiotherapy to Trigger Anti-Tumour Immunity
2+ hour, 13+ min ago (659+ words) A novel intravenous STING agonist, BI 1703880, synergises with radiotherapy and checkpoint inhibitors to generate durable anti-tumour immunity in preclinical mouse models....
Biologic Decision-Making for Moderate-to-Severe Atopic Dermatitis
5+ hour, 47+ min ago (773+ words) Hi, everybody. I'm Lisa Swanson. I'm a dermatologist and pediatric dermatologist in Boise, Idaho. I work at Ada West Dermatology, and I'm affiliated with St. Luke's Children's Hospital. Is today a good day, a bad day, a medium day? How…...
Can You Get Sunburned Through Clouds? UV on Overcast Days
1+ day, 4+ hour ago (642+ words) Can you get sunburned through clouds? Yes. Clouds soften visible light and warmth far more than they block ultraviolet, so a large share of UV still reaches your skin on grey days. Check the UV index rather than the sky,…...
Don't Be Rash: Balancing Topical Steroids in the Era of Nonsteroidals
8+ hour, 32+ min ago (450+ words) On this episode of Don’t Be Rash, host Andrew C. Krakowski, MD, welcomes Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical corticosteroid potency, dosing, and where they fit alongside nonsteroidal agents. Disclosure: Don’t Be Rash is the official podcast of…...
Once-Monthly Tezepelumab Shows Benefits in EoE
14+ hour, 45+ min ago (963+ words) NASHVILLE, Tenn. — Adults and adolescents with eosinophilic esophagitis (EoE) treated once-monthly with the monoclonal antibody tezepelumab showed significant improvements in symptoms, histology, and endoscopic measures compared with placebo, according to findings from the phase 3 CROSSING trial. The trial "met both…...